Summarized by Masters of Longevity from Longevity Docs News.
A briefing-style article about how regulators are shaping a research roadmap for aging and longevity, and what topics the reader can expect covered.
Key Takeaways
- FDA will publish a regulatory science focus document that explicitly names aging and longevity as topics of interest.
- Agency officials recommended initial trials target hard endpoints like prevention of age-related disease or death in high-risk groups.
- ARPA-H’s PROSPR program is funding trials and endpoint work with up to $144 million committed over five years.
